--- title: "New Pharmacological Pathways: FDA Approves Centanafadine (Simtriyo), a First-in-Class Non-Stimulant for ADHD" slug: centanafadine-simtriyo-fda-approval-adhd-2026 category: health category_label: "Health" author: "BrainWavePost Staff" date: 2026-07-25 tags: ["ADHD", "centanafadine", "Simtriyo", "FDA", "non-stimulant", "mental health", "pediatrics"] read_time_minutes: 8 canonical_url: https://brainwavepost.com/article/centanafadine-simtriyo-fda-approval-adhd-2026 source: BrainWavePost --- # New Pharmacological Pathways: FDA Approves Centanafadine (Simtriyo), a First-in-Class Non-Stimulant for ADHD *Health · 2026-07-25 · BrainWavePost Staff · 8 min read* > The FDA has approved Otsuka's centanafadine (Simtriyo), the first norepinephrine-dopamine-serotonin reuptake inhibitor for ADHD in adults and children aged 6 and older — expanding treatment options across pediatric, adolescent and adult patients. > **How this article is sourced** _(info)_ > > Every claim below is drawn from the U.S. Food and Drug Administration (FDA), Otsuka Pharmaceutical's official announcement, Psychiatric Times, the U.S. National Institute of Mental Health (NIMH), the American Academy of Pediatrics (AAP) and the CDC. Numbered citations link to the primary sources at the end. [1][2][3][4][5][6] On July 24, 2026, the U.S. Food and Drug Administration approved SIMTRIYO® (centanafadine) extended-release capsules for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and pediatric patients aged 6 years and older weighing at least 20 kg, according to Otsuka Pharmaceutical. [1][2] The drug is the first FDA-approved norepinephrine, dopamine and serotonin reuptake inhibitor (NDSRI); the FDA-approved labeling classifies it as a central nervous system (CNS) stimulant and carries a boxed warning for suicidal ideation and behaviors in pediatric patients and for abuse, misuse and addiction. [1][7] ## What ADHD is — and why more options matter ADHD is a common neurodevelopmental condition characterised by persistent inattention, hyperactivity and impulsivity that interferes with daily functioning. [3][4] The CDC estimates roughly 7 million U.S. children aged 3–17 have ever been diagnosed with ADHD, and NIMH data suggest around 4.4% of U.S. adults live with the condition. [4][5] Existing pharmacological options fall into two broad groups: stimulants (methylphenidate- and amphetamine-based products), which remain first-line for many patients, and non-stimulants such as atomoxetine, guanfacine and clonidine. [3][6] Clinical guidance from the American Academy of Pediatrics and NIMH emphasises that ADHD is heterogeneous: many patients respond only partially to first-line therapy, tolerate stimulants poorly, or need options with lower abuse liability. [3][6] That clinical gap is what a new mechanism of action aims to address. [2] ## How centanafadine works Centanafadine is a triple reuptake inhibitor that increases synaptic availability of norepinephrine, dopamine and serotonin — the same monoamine systems targeted, in different combinations, by existing ADHD medicines. [1][2] The approved label states the mechanism in ADHD is unclear but may be mediated by this triple reuptake inhibition, and lists centanafadine as a CNS stimulant whose controlled-substance schedule will be determined by the DEA. [7] ## What the phase 3 programme showed The approval was supported by four phase 3 randomised, placebo-controlled trials spanning ages 4–55: two in adults, one in adolescents (13–17) and one in children (4–12). [1][2] Key findings summarised by Otsuka and Psychiatric Times: [1][2] - In adults, both the 200 mg and 400 mg once-daily doses produced statistically significant, clinically meaningful reductions in the ADHD Investigator Symptom Rating Scale (AISRS) versus placebo at week 6. [1][2] - In children and adolescents, high-dose groups showed statistically significant improvements on the ADHD Rating Scale-5 (ADHD-RS-5) versus placebo at week 6. [1][2] - Post hoc analyses reported improvements in patient-reported executive-function domains including time management, planning and prioritisation, task initiation and completion, and working memory. [2] - **1st** — FDA-approved NDSRI for ADHD (Otsuka, FDA) [1][2] - **≥6 yrs** — approved age range, patients >20 kg [1][2] - **4 trials** — phase 3 studies across ages 4–55 [1][2] ## Safety and tolerability In the adult trials, commonly reported adverse reactions included headache, decreased appetite, insomnia, nausea, dry mouth and diarrhoea. [7] In the paediatric and adolescent trials, the most common adverse reactions were rash, decreased appetite, nausea, headache and abdominal pain. [7] The FDA-approved labeling — which patients and clinicians should consult for the complete list of boxed warnings, contraindications and monitoring recommendations — is the definitive source for prescribing information. [7] > **Important clinical context** _(note)_ > > Approval of a new medication does not mean it is right for every patient. Treatment decisions in ADHD depend on age, symptom profile, comorbidities, prior medication response and personal preference, and should be made with a qualified clinician. This article summarises publicly reported data and does not constitute medical advice. [3][6] ## Where centanafadine fits in the treatment landscape Stimulants remain the most effective and best-studied class for ADHD in most guidelines, including those from the American Academy of Pediatrics. [3] Non-stimulants — atomoxetine (a selective norepinephrine reuptake inhibitor), and the alpha-2 agonists guanfacine and clonidine — are recommended when stimulants are not tolerated, produce inadequate response, or are clinically inappropriate. [3][6] Centanafadine adds a mechanistically distinct option that acts on all three monoamines and is approved across a broad age range in a single product. [1][7] Lenard A. Adler, MD, director of the adult ADHD program at NYU Langone Health, was quoted in the Otsuka announcement noting that ADHD is highly individualized and that 'having more therapeutic choices is important because treatment decisions should reflect the unique needs of each patient.' [1][2] > The approval of SIMTRIYO marks an important milestone for people living with ADHD, as it introduces a novel treatment approach for this condition. > > — John Kraus, MD, PhD — EVP and Chief Medical Officer, Otsuka Pharmaceutical Development & Commercialization [1] ## What patients and families should know - Centanafadine (Simtriyo) is a prescription-only medication; Otsuka says it will become available after DEA scheduling. [1][7] - It is approved for ADHD in adults and in children aged 6 and older who weigh at least 20 kg — not for younger children studied in trials. [1][7] - As with any new medication, monitor for changes in appetite, headache, mood, sleep and other side effects, and report concerns to a prescriber. [1][2] - It does not replace behavioural therapy, school supports or accommodations, which remain part of evidence-based ADHD care per AAP and NIMH guidance. [3][6] > **Editorial note** _(tip)_ > > This article is educational and does not replace individual medical advice. Please consult a qualified healthcare professional about diagnosis or treatment of ADHD. ## Sources and further reading - [1] Otsuka Pharmaceutical — 'Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older' (July 24, 2026): https://www.otsuka-us.com/otsuka-shares-fda-review-update-for-centanafadine - [2] Walters J. — 'FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults', Psychiatric Times (July 24, 2026): https://www.psychiatrictimes.com/view/fda-approves-centanafadine-for-adhd-in-children-adolescents-and-adults - [3] American Academy of Pediatrics — 'Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents' (Pediatrics, 2019): https://publications.aap.org/pediatrics/article/144/4/e20192528/81590/ - [4] U.S. Centers for Disease Control and Prevention — 'Data and Statistics About ADHD': https://www.cdc.gov/adhd/data/index.html - [5] U.S. National Institute of Mental Health — 'Attention-Deficit/Hyperactivity Disorder (ADHD)': https://www.nimh.nih.gov/health/statistics/attention-deficit-hyperactivity-disorder-adhd - [6] U.S. National Institute of Mental Health — 'Attention-Deficit/Hyperactivity Disorder: What You Need to Know': https://www.nimh.nih.gov/health/publications/attention-deficit-hyperactivity-disorder-what-you-need-to-know - [7] SIMTRIYO® (centanafadine) extended-release capsules — U.S. Full Prescribing Information, Otsuka America Pharmaceutical (revised 7/2026): https://otsuka-us.com/media/static/Simtriyo-PI.pdf - [8] U.S. Food and Drug Administration — 'Drugs@FDA: FDA-Approved Drugs' (search 'centanafadine' for label and approval documents): https://www.accessdata.fda.gov/scripts/cder/daf/ --- _Canonical article: [https://brainwavepost.com/article/centanafadine-simtriyo-fda-approval-adhd-2026](https://brainwavepost.com/article/centanafadine-simtriyo-fda-approval-adhd-2026) — © BrainWavePost. Educational content; see the article page for full disclaimers._